metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	nivolumab plus cabozantinib
	CheckMate 9ER, 2021 Ann Oncol. 2020;31(4). Abstract 696O N Engl J Med 2021 Mar 4;384(9):829-841. 2022 ASCO Genitourinary Cancers Symposium Lancet Oncol 2022; 23:292-303-. NCT03141177	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	Nivolumab and Cabozantinib	Sunitinib	patients with previously untreated advanced or metastatic RCC that had a clear cell component	323 / 328	some concern	conclusif	demonstrated 40 % decrease in deaths (OS) (PE) demonstrated 49 % decrease in progression or deaths (PFS) (PE) suggested 30 % decrease in deaths (OS) (extension) suggested 44 % decrease in PFS (extension) more... nivolumab (Opdivo) and cabozantinib (Cabometyx) demonstrated superior PFS, OS, and ORR compared with first-line sunitinib (Sutent) in patient with advanced clear cell renal cell carcinoma
metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)
versus everolimus
	nivolumab alone
	CheckMate 025, 2015 N Engl J Med 2015;373:1803-13 Jpn. J. Clin. Oncol. 2019; 49:506-514 Jpn. J. Clin. Oncol. 2017; 47:639-646 Eur. Urol. 2017; 72:368-376 Eur. Urol. 2017; 72:962-971 Lancet Oncol. 2016; 17:994-1003 NCT01668784	RCT	metastatic/advanced RCC (mRCC) - 2nd line (L2)	nivolumab	everolimus	patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy	410 / 411	some concern	conclusif	demonstrated 27 % decrease in deaths (OS) (PE) demonstrated 5.0-fold increase in objective responses (ORR) (PE)